Erin Toaz

Dr. Erin Toaz

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2023 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
ETErin Toaz
Erin Toaz
ECEric Cheon
Eric Cheon
NHNatalie V. Hoffmann
Natalie V. Hoffmann
JPJohn E. Pandolfino
John E. Pandolfino
DCDustin A Carlson
Dustin A Carlson
JWJoshua B. Wechsler
Joshua B. Wechsler

17 November 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
ETErin Toaz
Erin Toaz
ABAlain J. Benitez
Alain J. Benitez
ECEric C. Cheon
Eric C. Cheon
MMMark Mahon
Mark Mahon
NHNatalie V. Hoffmann
Natalie V. Hoffmann
JWJoshua B. Wechsler
Joshua B. Wechsler
INTRODUCTION: Functional lumen imaging probe (FLIP) can assess the esophageal contractile response (CR). Anesthetic agents used during endoscopy affect esophageal contractility, however, the time or dose-dependent effect of specific medications on the esophageal CR in children is unknown. METHODS: Charts of patients aged 3–22 years undergoing endoscopy with FLIP for evaluation of dysphagia at 2 tertiary pediatric hospitals were reviewed. Anesthetic dose and timing were collected. FLIP data were exported to Wklytics to generate Panometry plots, and the CR was classified as normal, borderline, spastic, impaired, or absent based on established definitions. Binary logistic regression was performed to assess whether anesthetic administration was associated with absent CR. End-tidal sevoflurane concentration was compared across groups with normal, borderline, and absent/impaired CR. RESULTS: Three hundred-three pediatric patients with a mean (SD) age of 13 years (4), 65% adolescent boys, were included. Totally, 80 (26%) had abnormal esophageal CR, where 16 (5%) were impaired, 63 (21%) were absent, and 1 was spastic. Two hundred twenty-eight (75%) were diagnosed with eosinophilic esophagitis, and 215 (71%) received sevoflurane. The odds ratio for absent CR if sevoflurane was administered was 8.4 ( P < 0.001). Sevoflurane was used significantly more often for both induction and maintenance in patients with abnormal CR compared with normal CR (70% vs 38%, P < 0.001). During the maintenance phase of anesthesia, end-tidal sevoflurane concentration was higher in patients with abnormal CR compared with normal CR independent of propofol infusion, recruitment site, and distensibility. DISCUSSION: The timing and dose of sevoflurane is strongly associated with esophageal CR impairment during FLIP.

4 September 2026 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
MAMeron Amariw
Meron Amariw
HBHeather A. Ballard
Heather A. Ballard
ETErin Toaz
Erin Toaz
Was not provided for this article.

18 September 2025 in Children
Verified
Journal Article
Open access
PDF file
ETErin Toaz
Erin Toaz
NPNisha Pinto
Nisha Pinto
KKKeith Kilner
Keith Kilner
ECEric Cheon
Eric Cheon
Background/Objectives: Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease resulting in proximal muscle weakness and paralysis. SMA treatment has radically changed in the past 10 years thanks to the development of novel therapies such as nusinersen and onasemnogene abeparvovec. Since the advent of new treatments, the incidence and perioperative risk factors of patients with SMA undergoing longer, higher-risk surgeries are unknown. We hypothesized that patients with SMA would be at an overall elevated risk for postoperative pulmonary complications (PPC) and prolonged length of stay compared to the general population, but that this would be reduced in patients undergoing surgery in the years after the release of new therapies. Methods: Patients who underwent surgery at a continuously enrolled American College of Surgeons National Surgery Quality Improvement Program-Pediatric hospital from 1 January 2012, to 31 December 2021, were included in this study. Cases with missing covariate or primary outcome data were excluded from the analysis. Patients with ages greater than 17 years, preoperative tracheostomy, preoperative mechanical ventilation, missing covariate or primary outcome data were excluded. Patients with SMA were identified by their ICD-9 and 10 codes. A cutoff year of 2018 was chosen for analysis of the primary outcomes as this was a full year after nusinersen received FDA approval. Results: On univariable analysis, the risk for PPC in patients with SMA was reduced in patients undergoing surgery in 2018 or later compared to pre-2018 (pre-2018 OR 4.44, 95% CI 1.56–9.6, p = 0.008; post-2018 OR 3.48, 95% CI 0.84–9.12, p = 0.08). On multivariable analysis, the association between SMA and PPC substantially decreased in 2018 and after but was no longer statistically significant (pre-2018 OR 1.96, 95% CI 0.80–4.80, p = 0.14; post-2018 OR 1.03, 95% CI 0.33–3.26, p = 0.96). SMA was positively associated with LOS in the pre-2018 cohort, with a coefficient from a log linear model of 0.67 (95% CI 0.32–1.01; p < 0.001), and SMA adding an additional 1.93 days in LOS. For data post-2018, the effect of SMA on LOS was no longer statistically significant. Conclusions: Utilizing a large dataset, we found a reduced association between SMA and PPC a year following widespread implementation of SMN antisense oligonucleotide therapy, and a statistically significant reduction in LOS in patients with SMA after 2018. This may reflect improved motor outcomes and respiratory mechanics in the new treatment era.

24 November 2023 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
ETErin Toaz
Erin Toaz
NPNisha Pinto
Nisha Pinto
VRVamshi K. Rao
Vamshi K. Rao
ECEric Cheon
Eric Cheon